DUBLIN – After 18 months in stealth mode, Montreal-based Repare Therapeutics Inc. has emerged with $68 million in series A funding and serious ambitions to become a leader in identifying small-molecule drugs that act on novel targets identified through CRISPR-based induction and screening of mutations that give rise to synthetic lethality.